Loading...
•
Jun 30, 2024
Immunovant Q1 2025 Earnings Report
Immunovant reported corporate updates and financial results for the first quarter ended June 30, 2024.
Key Takeaways
Immunovant reported a net loss of $87.2 million for the quarter ended June 30, 2024. As of June 30, 2024, cash and cash equivalents totaled approximately $560 million. The company completed enrollment in the batoclimab pivotal Myasthenia Gravis (MG) trial and progressed the development of IMVT-1402.
Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025).
Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024).
Progressed Graves’ disease (GD) program and on track to disclose additional results from the batoclimab study in GD as well as an overview of our development program for IMVT-1402 in GD in the fall of 2024.
As of June 30, 2024, Immunovant’s cash and cash equivalents totaled approximately $560 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...